Pharmacogenomic strategy for individualizing antidepressant therapy

Keh Ming Lin, Roy H. Perlis, Yu-Jui Yvonne Wan

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Despite remarkable progress, pharmacotherapy in general, including that for the treatment of depressive conditions, has often ignored the magnitude and clinical significance of the huge interindividual variations in pharmacokinetics and pharmacodynamics, resulting in poor compliance, suboptimal therapeutic effects, and treatment resistance. Advances in pharmacogenomics and computer modeling technologies hold promise for achieving the goals of "individualized" ("personalized") medicine. However, the challenges for realizing such goals remain substantial. These include the packaging and interpretation of genotyping results, changes in medical practice (innovation diffusion), and infrastructural, financing, ethical, and organizational issues related to the use of new information.

Original languageEnglish (US)
Pages (from-to)401-408
Number of pages8
JournalDialogues in Clinical Neuroscience
Issue number4
StatePublished - 2008
Externally publishedYes


  • Antidepressant
  • Individualized medicine
  • Personalized medicine
  • Pharmacogenetic
  • Pharmacogenomic
  • Psychopharmacology
  • Treatment response

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Pharmacogenomic strategy for individualizing antidepressant therapy'. Together they form a unique fingerprint.

Cite this